This report was first published by Endpoints News. To see the original version, click here
Eli Lilly is making moves in East Asia.
The Indianapolis drugmaker said Wednesday it is earmarking $3 billion over the next decade to increase its manufacturing footprint in China. Earlier this week, Lilly said it is investing $500 million in South Korea over the next five years through a memorandum of understanding with the government.
您已阅读17%（427字），剩余83%（2050字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。